Skip to main content
SpringerLink
Log in

Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report

  • Meeting Report
  • Theme: Dissolution and Translational Modeling Strategies Enabling Patient-Centric Product Development
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

On May 15th–17th, 2017, the US FDA and the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) held a workshop at the University of Maryland’s Center of Excellence in Regulatory Science and Innovation (M-CERSI), to discuss the role of dissolution testing and translational modeling and simulation in enabling patient-centric solid oral drug product development. This 3-day event was attended by scientists from regulatory agencies, pharmaceutical companies, and academia. The workshop included podium presentations followed by breakout session discussions. The first day of the meeting focused on the challenges in dissolution method development and the role of dissolution testing throughout drug product development. On the second day, approaches to establish a link between in vitro testing and in vivo drug product performance (e.g., systemic exposure) were presented. Overall success rates and challenges in establishing IVIVCs via traditional and modern physiologically based pharmacokinetic (PBPK) modeling and simulation approaches were discussed. Day 3 provided an opportunity to discuss the expectations for establishing clinically relevant drug product specifications (CRDPS). It was recognized that understanding the impact of formulation and process variations on dissolution and in vivo performance is critical for most drug products formulated with poorly soluble drugs to ensure consistent product performance. The breakout sessions served as platforms for discussing controversial topics such as the clarification of dissolution terminology, PBPK model development and validation expectations, and approaches to set CRDPS. The meeting concluded with a commitment to continue the dialog between regulators, industry, and academia to advance overall product quality understanding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. By following this link, the interested reader can access the workshop agenda and all meeting materials (presentations). Alternatively, the agenda can be found following by clicking on the following link: http://pharmacy.umaryland.edu/centers/cersievents/dissolution-and-translational-modeling-strategies/

References

  1. Miksinski SP. New drug applications: the evolution of quality review, in 2nd FDA/PQRI Conference on advancing product quality. 2015: Bethesda, MD.

  2. Selen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, et al. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. J Pharm Sci. 2014;103(11):3377–97.

    Article  PubMed  CAS  Google Scholar 

  3. United States Pharmacopeia and the National Formulary (USP-NF). Chapter 711 in US Pharmacopeial Convention. 2015. Rockville, MD.

  4. Takeuchi S, Tsume Y, Amidon GE, Amidon GL. Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution. J Pharm Sci. 2014;103(11):3416–22.

    Article  PubMed  CAS  Google Scholar 

  5. U.S. Department of Health and Human Services—Food and Drug Administration, CDER., Guidance for industry—dissolution testing of immediate release solid oral dosage forms. 1997.

  6. U.S. Department of Health and Human Services—Food and Drug Administration, CDER. Guidance for industry-extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations. 1997.

  7. Miksinski SP. Clinical relevance—seeing the big picture, in dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  8. Ju R, Grady H. Industry perspective on the current status and future of dissolution testing for product development and quality control, In Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  9. Kuiper J, Coutant C. Use of bio-predictive methods during early formulation screening with case studies, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  10. Lu X, J.-H. Han, and D. Mattocks, Dissolution methodologies from biorelevant to quality control: Challenges and gaps, in dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  11. Zhang L, Hermans A The use of surrogates for dissolution testing for IR formulations: when is it feasible?, in Dissolution and Translational Modeling Strategies enabling Patient-Centric Product Development. 2017: Baltimore, MD.

  12. Li H, Prichard J, Swinney KA. Dissolution modeling for real time release testing (RTRT), in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  13. Drazer G, et al. Enabling real time release testing (RTRt) with NIR-based prediction of dissolution for tablets made by continuous direct compression (CDC), in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  14. Seo P. Challenges and strategies in establishing an in-vitro in-vivo link, in dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  15. Montague TH. Novel approaches in human PK study design (e.g. stable isotopes technique) to overcome the challenges in the conduct of dedicated BA/BE studies (case studies), in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  16. Suarez-Sharp S, Li M, Duan J, Shah H, Seo P. Regulatory experience with in-vivo in-vitro correlations (IVIVC) in new drug applications. AAPS J. 2016;18(6):1379–90.

    Article  PubMed  CAS  Google Scholar 

  17. Van Buskirk GA, Shah V. PQRI workshop report: application of IVIVC in formulation development. Dissolut Technol. 2014;21(2):51–8.

    Article  Google Scholar 

  18. Maziar K. Application of stochastic deconvolution in IVIVC development, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  19. Nordmark A. EMA draft guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) Modelling and simulation, in dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  20. Huang W, Sau LL, Yu LX. Mechanistic approached to predicting oral drug absorption. AAPS J. 2009;11(2):217–24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:300–21.

    Article  PubMed  CAS  Google Scholar 

  22. Olivares-Morales A, Parrott N, Stillhart C. Case studies of mechanistic absorption modeling and IVIVC, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  23. Holmstock N. Development of canagliflozin: mechanistic absorption modeling during late-stage formulation and process optimization: mechanistic absorption modeling during late-stage formulation and process optimization in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  24. Pepin XJH, Flanagan TR, Holt DJ, Eidelman A, Treacy D, Rowlings CE. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for Lesinurad immediate release tablets. Mol Pharm. 2016;13(9):3256–69.

    Article  PubMed  CAS  Google Scholar 

  25. Lin H-P. The utility of in silico PBPK absorption modeling and simulation as a tool to increase the success of developing bio-predictive dissolution methods: success and limitations (case studies from regulatory perspective), in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  26. Zhao L, Tsakalozou E. The utility of in silico PBPK absorption modeling and simulation as a tool to develop bio-predictive dissolution methods, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  27. Li M, Zhao P, Pan Y, Wagner C. Predictive performance of physiologically based pharmacokinetic models for the effect of food on oral drug absorption: current status. CPT Pharmacometrics Syst Pharmacol. 2017;7(2):82–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Heimbach T, He H. PBPK modeling and simulations of oral drug absorption/food effect/PPI /PBIVIVC: opportunities and challenges, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  29. Einolf HJ, Lin W, Won CS, Wang L, Gu H, Chun DY, et al. Physiologically based pharmacokinetic model predictions of panobinostat (LBH589) as a victim and perpetrator of drug-drug interactions. Drug Metab Dispos. 2017;45(12):1304–16.

    Article  PubMed  CAS  Google Scholar 

  30. Li M. Biorelevant dissolution testing for in vitro in vivo correlation/relationship (IVIVC/R) development: regulatory perspective, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  31. Suarez-Sharp S. Paving the road towards setting clinically relevant specifications: biopharmaceutics perspectives on information needed, approach, and Criteria, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  32. Kotzagiorgis E. Framework of setting clinically relevant specifications: approach, information needed, and criteria in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  33. Abend A. Framework for setting clinically relevant dissolution specifications (CRS), in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  34. Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, et al. Approaches for establishing clinically relevant dissolution specifications during drug development. AAPS J. 2017;19(6):1537–49.

    Article  PubMed  CAS  Google Scholar 

  35. Cohen M. The role of bio-predictive dissolution methods in the selection of CMAs, CPPS, and verification of design space (S): case studies, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  36. Kesisoglou F. The utility of on level C IVIVC for setting clinically relevant specifications: case studies and implications, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  37. Davit B. Case study: use of in vivo pharmacokinetic data to develop a crs for in vitro dissolution testing, in Dissolution and translational modeling strategies enabling patient-centric product development. 2017: Baltimore, MD.

  38. Marroum P Establishing clinically relevant specifications during product life cycle: case studies in Dissolution and Translational Modeling Strategies enabling Patient-Centric Product Development. 2017: Baltimore, MD.

  39. European Medicines Agency, Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and SIMULATION 2016.

  40. U.S. Department of Health and Human Services - Food and Drug Administration, CDER. Physiologically based pharmacokinetic analyses—format and content; draft guidance for industry. 2016.

Download references

Acknowledgments

The meeting organizers are indefinitely grateful to Drs. James Polli (University of Maryland, School of Pharmacy, Baltimore, MD), Tzuchi (Rob) Ju (AbbVie, Inc.), Mr. Evangelos Kotzagiorgis (EMA), and Ms. Ann Anonson (UM) for their tremendous efforts in helping in the organization of this workshop and to all speakers, facilitators, and scribes whose participation was key in having a very informative workshop.

Author information

Authors and Affiliations

  1. Pharmaceutical Sciences, Merck, 770 Sumneytown Pike, West Point, Pennsylvania, 19486, USA

    Andreas Abend & Filippos Kesisoglou

  2. Novartis Institutes for Biomedical Research, One Health Plaza, East Hanover, New Jersey, 07936, USA

    Tycho Heimbach

  3. Pfizer Inc, Eastern Point Road, Groton, Connecticut, 06340, USA

    Michael Cohen

  4. AstraZeneca R&D, Macclesfield, Cheshire, UK

    Xavier Pepin

  5. Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA

    Sandra Suarez-Sharp

Authors
  1. Andreas Abend
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tycho Heimbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Filippos Kesisoglou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xavier Pepin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sandra Suarez-Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandra Suarez-Sharp.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest to declare.

Disclaimer

This article reflects the views of the authors and should not be construed to represent their organizations’ views or policies.

Additional information

Guest Editors: Marilyn N. Martinez, Sandra Suarez, and Andreas Abend

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abend, A., Heimbach, T., Cohen, M. et al. Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report. AAPS J 20, 60 (2018). https://doi.org/10.1208/s12248-018-0213-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-018-0213-x

KEY WORDS

Search

Navigation